Compare SHASUN PHARMA with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs BIOCON - Comparison Results

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA BIOCON SHASUN PHARMA/
BIOCON
 
P/E (TTM) x 123.9 22.5 550.9% View Chart
P/BV x 8.5 3.0 286.4% View Chart
Dividend Yield % 0.2 0.4 60.0%  

Financials

 SHASUN PHARMA   BIOCON
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
BIOCON
Mar-18
SHASUN PHARMA/
BIOCON
5-Yr Chart
Click to enlarge
High Rs941,188 7.9%   
Low Rs46305 15.0%   
Sales per share (Unadj.) Rs214.268.7 311.7%  
Earnings per share (Unadj.) Rs5.37.6 70.7%  
Cash flow per share (Unadj.) Rs15.814.0 113.2%  
Dividends per share (Unadj.) Rs1.001.00 100.0%  
Dividend yield (eoy) %1.40.1 1,068.0%  
Book value per share (Unadj.) Rs53.386.3 61.8%  
Shares outstanding (eoy) m56.62600.00 9.4%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x0.310.9 3.0%   
Avg P/E ratio x13.198.9 13.3%  
P/CF ratio (eoy) x4.453.4 8.3%  
Price / Book Value ratio x1.38.6 15.2%  
Dividend payout %18.713.2 141.5%   
Avg Mkt Cap Rs m3,958447,900 0.9%   
No. of employees `000NA6.1 0.0%   
Total wages/salary Rs m2,1649,311 23.2%   
Avg. sales/employee Rs ThNM6,705.8-  
Avg. wages/employee Rs ThNM1,514.2-  
Avg. net profit/employee Rs ThNM736.9-  
INCOME DATA
Net Sales Rs m12,12741,234 29.4%  
Other income Rs m2292,062 11.1%   
Total revenues Rs m12,35643,296 28.5%   
Gross profit Rs m1,0098,291 12.2%  
Depreciation Rs m5943,851 15.4%   
Interest Rs m415615 67.5%   
Profit before tax Rs m2305,887 3.9%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-731,569 -4.6%   
Profit after tax Rs m3024,531 6.7%  
Gross profit margin %8.320.1 41.4%  
Effective tax rate %-31.726.7 -118.8%   
Net profit margin %2.511.0 22.7%  
BALANCE SHEET DATA
Current assets Rs m6,88441,486 16.6%   
Current liabilities Rs m8,45621,413 39.5%   
Net working cap to sales %-13.048.7 -26.6%  
Current ratio x0.81.9 42.0%  
Inventory Days Days6264 96.4%  
Debtors Days Days10894 114.2%  
Net fixed assets Rs m4,97050,661 9.8%   
Share capital Rs m1133,000 3.8%   
"Free" reserves Rs m2,87548,808 5.9%   
Net worth Rs m3,02051,808 5.8%   
Long term debt Rs m1,81717,898 10.2%   
Total assets Rs m13,34799,897 13.4%  
Interest coverage x1.610.6 14.7%   
Debt to equity ratio x0.60.3 174.2%  
Sales to assets ratio x0.90.4 220.1%   
Return on assets %5.45.2 104.3%  
Return on equity %10.08.7 114.4%  
Return on capital %13.39.6 138.3%  
Exports to sales %46.40-   
Imports to sales %14.20-   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,728NA-   
Fx inflow Rs m5,84312,058 48.5%   
Fx outflow Rs m2,1737,348 29.6%   
Net fx Rs m3,6694,710 77.9%   
CASH FLOW
From Operations Rs m3986,621 6.0%  
From Investments Rs m-1,635-6,840 23.9%  
From Financial Activity Rs m1,309-2,397 -54.6%  
Net Cashflow Rs m71-2,612 -2.7%  

Share Holding

Indian Promoters % 39.2 40.4 97.0%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 3.6 8.4 42.9%  
FIIs % 17.6 10.7 164.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 19.9 199.0%  
Shareholders   20,750 109,995 18.9%  
Pledged promoter(s) holding % 12.3 0.0 30,725.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   CIPLA  PIRAMAL ENTERPRISES  NATCO PHARMA  SUN PHARMA  PFIZER  

Compare SHASUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)

Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.

Related Views on News

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS